CN113209357B - Composite styptic powder - Google Patents
Composite styptic powder Download PDFInfo
- Publication number
- CN113209357B CN113209357B CN202110531300.2A CN202110531300A CN113209357B CN 113209357 B CN113209357 B CN 113209357B CN 202110531300 A CN202110531300 A CN 202110531300A CN 113209357 B CN113209357 B CN 113209357B
- Authority
- CN
- China
- Prior art keywords
- formula
- hemostatic powder
- amino
- powder
- composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/08—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Abstract
The invention provides composite hemostatic powder, which is formed by mixing synthetic molecules 1, synthetic molecules 2 and water-absorbing powder, wherein the synthetic molecules 1 and the synthetic molecules 2 can react with each other to form gel in the presence of blood, so that the strength and the interaction capacity with tissues of the hemostatic powder are enhanced. The composite hemostatic powder can absorb a large amount of water, and the degradation time can be adjusted to be suitable for different bleeding positions and bleeding degrees.
Description
Technical Field
The invention relates to a composite hemostatic powder system, in particular to a composite hemostatic powder system based on controllable cross-linking and degradation synthetic material powder and water-absorbing powder, and a preparation method and application thereof.
Background
Throughout the development of hemostatic materials, the following four stages are experienced: one is a non-degradable material represented by vaseline oil yarn, which is simple to manufacture and is packed by compression to stop bleeding. The hemostatic material has poor hemostatic effect, is non-degradable, is easy to adhere to the blood crust, and is easy to cause the blood crust to fall off in the process of taking out, thereby causing secondary bleeding. The other is non-degradable hydrogel material, represented by PVA, which has good blood sucking performance, but also has the problem of secondary bleeding caused by non-degradation during the taking out process. Third, degradable natural high molecular material, mainly polysaccharide such as starch, alginic acid, chitosan, etc., and protein such as collagen, etc. The material has good biocompatibility, can be absorbed by a human body in vivo, and does not need to be taken out for the second time, so that the problem of secondary bleeding of the wound caused in the process of taking out the material is avoided. However, the natural polymer has a large amount of hydrogen bonds, so that the hemostatic material has high rigidity, and the prepared sponge has high brittleness and poor elasticity, and the used patient has foreign body sensation and poor postoperative comfort. And the protein hemostatic materials such as collagen from animal bodies have potential risks such as in vivo immune activation, microbial and viral infection and the like. The biodegradable polyurethane thermoplastic elastomer represented by poly-epsilon-caprolactone/lactide-urethane is taken as a fourth generation hemostatic material, and has the advantages of good elasticity, good hemostatic effect, degradability, outflow, no adhesion in a lumen, no need of cleaning and the like. Is a novel lumen hemostatic material which is competitively developed by scientists in various countries in recent years.
However, the existing hemostatic materials still have the disadvantages of slow degradation speed, insufficient strength, etc., so that it is necessary to develop new hemostatic materials to obtain the desired performance.
Disclosure of Invention
The invention aims to provide composite hemostatic powder based on controllable crosslinking and degrading synthetic material powder and hemostatic powder, and a preparation method and application thereof.
A composite styptic powder is prepared from two molecules of polyoxyethylene-polyoxypropylene block copolymer, polyacrylic acid and polyethylene glycol derivative, synthetic molecule 1 and synthetic molecule 2 through mixing, chemical bond connection can be formed between synthetic molecule 1 and synthetic molecule 2 through chemical reaction in blood to form gel, the strength of the styptic powder is enhanced, and interaction with tissues occurs, wherein the styptic powder can be water-absorbing substances such as natural polysaccharides and proteins and derivatives thereof.
In the composite hemostatic powder, the synthetic molecule 1 can be any one of a formula I, a formula II and a formula III:
in each formula, m, n and p can be 28 to 123, x represents the number of arms and can be 1 to 8.
Wherein R is 1 Is amino, succinimide ester, aldehyde group, sulfhydryl, alkenyl, alkynyl, acrylate group, methylAny one of the acrylate groups, in some embodiments, R 1 Is amino, succinimidyl ester, mercapto, alkynyl or azido group;
in some embodiments, the synthetic molecule 1 may be any one of the following formulas 1) to 4):
1) Shown as formula I, wherein m is 10-35, n is 28-123, p is 10-50, x is 4 1 Is amino, aldehyde or succinimide ester;
2) As shown in formula II, where m is 38 to 112, in some embodiments m is 56, x is 2 to 4 1 Is amino, mercapto or aldehyde group;
3) As shown in formula III, wherein m is 36, x is 2 1 Is an amino group.
In some embodiments, the synthetic molecule 2 in the composite hemostatic powder may be any one of formula IV, formula V, and formula VI:
in the formula, m, n and p are 2-88, x represents the number of arms is 1-8, specifically 2, 4 and 6, wherein R 2 Is any one of amino, carboxyl, succinimidyl ester, aldehyde group, mercapto, alkenyl, alkynyl, acrylate group, preferably amino, succinimidyl ester, mercapto, alkynyl or azide group.
The synthetic molecule 1 and the synthetic molecule 2 are connected via R 1 And R 2 Are chemically reacted.
The synthetic molecule 2 of the invention can be any one of the following 1) to 4):
1) As shown in formula IV, wherein m is 10-52, n is 12-20, p is 30-98, x is 4 2 Being succinimidyl esters, amino or mercapto groups
2) Shown as formula V, wherein m is 28-88, x is 4 2 Is amino, alkenyl or succinimide ester
3) The formula is shown as formula VI, wherein m is 28-88, x is 1, R is amino, succinimide ester or aldehyde group.
In some embodiments, the composite hemostatic powder is composed of a compound shown in formula III and a compound shown in formula V, wherein m is 36, x is 4, and R1 is amino or alkynyl; in the compound shown in the formula V, m is 28-46, x is 4 2 Is amino, alkenyl or succinimide ester.
In some embodiments, the composite hemostatic powder consists of a compound shown as a formula II and a compound shown as a formula VI or a compound shown as a formula IV, wherein m in the compound shown as the formula II is 70-112, x is 2-4, R is 1 Is amino, mercapto or aldehyde group; in the compound shown in the formula VI, m is 56, x is 4, and R2 is alkenyl; in the compound shown in the formula IV, m is 52, n is 12, p is 98 and x is 2.
In the composite hemostatic powder system based on the controllable cross-linking and degrading synthetic material powder and the hemostatic powder, the average particle size of the synthetic molecules 1 and 2 can be 0.01-10 mu m.
In the composite hemostatic powder, the hemostatic powder can be commercial hemostatic powder such as regenerated cellulose hemostatic powder, chitosan hemostatic powder, starch hemostatic powder, collagen hemostatic powder, zeolite hemostatic powder, and the like, and specifically can be: fuhe and Tai degradable hemostatic powder, meisiter quick-acting hemostatic powder, languan hemostatic powder, alista hemostatic powder, aiwei Titing microfiber hemostatic collagen, quikClot and the like, and also can be water-absorbing powder, such as polysaccharide and derivatives thereof, and protein and derivatives thereof.
The polysaccharide or its derivative can be agar, agarose, sodium alginate, cellulose, starch, hyaluronic acid or their derivatives.
The proteins and their derivatives may be collagen, gelatin, thrombin, fibrin or their derivatives.
In some embodiments, the synthetic molecule 1, the synthetic molecule 2 and the water-absorbing powder are uniformly mixed according to a certain proportion, so that a composite hemostatic powder system based on the synthetic material powder and the water-absorbing powder with controllable crosslinking and degradation can be prepared.
In some embodiments, the mass ratio of the synthetic molecule 1, the synthetic molecule 2 and the water absorbent powder can be 0.01-10: 0.1-10: 0.01-10, in some embodiments 0.1-2: 0.1-2, in some embodiments 1: 1, and in other embodiments 1: 2: 1.
The composite hemostatic powder system based on the controllable cross-linking and degrading synthetic material powder and the water absorbing powder has controllable degradation time in a simulated body fluid environment and in vivo, and the degradation period is 1 hour to 10 days.
The composite hemostatic powder system based on the controllable cross-linking and degrading synthetic material powder and the water absorbing powder provided by the invention has potential application in the following fields:
(1) Medical sponge;
(2) Epidermal hemostasis;
(3) Organ hemostasis;
(4) Arterial hemostasis;
compared with the prior art, the invention has the following beneficial effects:
(1) Compared with the commercially available hemostatic powder, the composite hemostatic powder has higher water absorption capacity, can quickly absorb blood at a wound bleeding part, concentrates blood coagulation factors and blood cells, and quickly activates endogenous blood coagulation;
(2) The composite hemostatic powder can closely interact with tissues, can be closely attached to the position of a wound to form a physical barrier layer, prevents blood from continuously flowing out, and does not need an additional method to fix the composite hemostatic powder;
(3) The degradation time of the composite hemostatic powder can be regulated and controlled, and the hemostatic requirements of wounds at different positions and different degrees are met;
(4) The composite hemostatic powder has good biocompatibility.
Description of the drawings:
FIG. 1 shows a block experimental diagram of femoral artery of pig according to the embodiment of the present invention.
Detailed Description
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Examples 1,
Weighing 140mg of four-arm polyethylene glycol amino group (shown as formula III, wherein m is 36, x is 4, and R is 1 Amino group) with a particle size of 1 μm, and 110mg of a four-arm polyacrylamide (as shown in formula V, wherein m is 46, x is 4, R is weighed 2 Succinimidyl ester) with the particle diameter of 2 mu m, and uniformly mixing the synthetic powder with 100mg of starch water-absorbing powder to obtain the composite hemostatic powder.
And (3) degradation testing: and (3) putting the absorbed composite hemostatic powder into a PBS (phosphate buffer solution) solution with the mass being 10 times that of the absorbed composite hemostatic powder, then putting the composite hemostatic powder into a constant-temperature shaking table at 37 +/-1 ℃, and observing the change condition of a gel sample in a buffer solution at the speed of 100r/min until no precipitate is seen after centrifugation, wherein the time is recorded as the gel in-vitro degradation time.
After the composite hemostatic powder prepared in the embodiment absorbs water, the composite hemostatic powder is gelatinous and can be well attached to the surface of skin, and the in-vitro degradation time is 5 days.
Examples 2,
Weighing 200mg of six-arm polyoxyethylene polyoxypropylene amino (shown as formula I, wherein m is 10, n is 123, p is 50, x is 6, R is 1 Amino group) with a particle size of 0.2 μm, weighing 200mg of two-arm polyoxyethylene polyoxypropylene succinimide ester (shown in formula IV, wherein m is 10, n is 20, p is 30, x is 2, and R2 is succinimide ester) with a particle size of 0.5 μm, and mixing the two synthetic powders and 200mg of chitosan water absorption powder uniformly to obtain the composite hemostatic powder.
Water absorption capacity test method: mixing a certain mass of hemostatic powder, then spreading the mixture in a culture dish, and adding ultrapure water immersed hemostatic powder into the culture dish. And taking out the gelatinized hemostatic powder every other hour, wiping off the residual water on the surface, weighing the gel, weighing for 5 times, and taking the average value as the weighing mass. The weighed gel is placed in a culture dish and water is added again to swell the gel. The final mass was recorded as the three consecutive weighed masses no longer changed. The water absorption capacity calculation method is as follows:
HE: water absorption expansion times;
wt: the final quality of the hemostatic powder after water absorption and expansion;
w0: initial quality of the styptic powder before water absorption.
The water absorption capacity of the composite hemostatic powder prepared in the example is 300 times of that of the chitosan water absorption powder, after water absorption, the composite hemostatic powder is gelatinized, and the in vitro degradation time is 3 days.
Examples 3,
Weighing 100mg of eight-arm polyacrylamide amino (shown as formula II, wherein m is 38, x is 8, R is 1 Is amino group) with a particle size of 1.5 μm, 200mg of eight-arm polyacrylamide succinimidyl ester (shown in formula V, wherein m is 88, x is 8, R is weighed 2 Succinimide activated ester) with a particle diameter of 1.5 μm, and mixing the two synthetic powders with 500mg arista TM hemostatic powder to obtain composite hemostatic powder.
The water absorption capacity of the composite hemostatic powder prepared in the embodiment is 200 times, which is higher than that of a single Arista TM hemostatic powder sold in the market (70 times), after water absorption, the composite hemostatic powder is gelatinous, and the in vitro degradation time is 4 days.
Examples 4,
Weighing 400mg six-arm polyoxyethylene polyoxypropylene aldehyde group (shown as formula I, wherein m is 35, n is 28, p is 10, x is 6, R is shown as the formula I) 2 Aldehyde group) with a particle size of 1.9 μm, 400mg of six-armed polyoxyethylene polyoxypropylene amino (represented by formula IV, wherein m is 28, n is 16, p is 60, x is 6, and R is 2 Amino group) with the particle size of 1.9 μm, and mixing the two synthetic molecules with 400mg of QuikClot hemostatic powder sold in the market to obtain the composite hemostatic powder.
The water absorption capacity of the composite hemostatic powder prepared in the embodiment is 198 times, which is higher than that (45 times) of the single QuikClot hemostatic powder sold in the market, and after water absorption, the composite hemostatic powder is gelatinous, and the in vitro degradation time is 4 days.
Examples 5,
150mg of four-arm polyacrylamide mercapto group (shown as formula II, wherein m is 112, x is 4 1 Mercapto group) with a particle size of 1.9 μm, and 150mg of a four-arm polyethylene glycol alkenyl group (shown in formula VI, wherein m is 56, x is 4, R is weighed 2 Alkenyl) with the grain diameter of 2.2 mu m, and uniformly mixing the two synthetic molecular powders with 400mg of chitosan hemostatic powder sold in the market to obtain the composite hemostatic powder.
The water absorption capacity of the composite hemostatic powder prepared in the embodiment is 140 times, which is higher than that (45 times) of the single chitosan hemostatic powder sold in the market, after water absorption, the composite hemostatic powder is gelatinized, and the in vitro degradation time is 5 days.
Examples 6,
100mg of a four-arm polyethylene glycol succinimide ester (shown in formula III, wherein m is 36, x is 4 1 Alkynyl) with a particle size of 0.03 μm, and 100mg of a four-arm polyacrylamide (shown by formula V, wherein m is 28, x is 4, R is weighed 2 Amino group) with the grain diameter of 0.02 mu m, and uniformly mixing the two synthetic powders with 500mg of starch hemostatic powder to obtain the composite hemostatic powder.
The water absorption capacity of the composite styptic powder prepared in the embodiment is 290 times, which is higher than that (50 times) of the single starch styptic powder sold in the market, and after water absorption, the composite styptic powder becomes colloid, and the in vitro degradation time is 4 days.
Example 7,
Weighing 300mg of four-arm polyacrylamide mercapto (shown as formula II, wherein m is 70 1 Sulfydryl, x is 2), the particle size is 0.6 μm, 200mg of double-arm polyoxyethylene polyoxypropylene succinimide ester (shown as formula IV, wherein m is 52, n is 12, p is 98, x is 2) is weighed and has the particle size of 0.2 μm, and the two synthetic powders are uniformly mixed with 500mg of commercially available Arista TM hemostatic powder to prepare the composite hemostatic powder.
The water absorption capacity of the composite hemostatic powder prepared in the embodiment is 456 times, which is far higher than that of a single Arista (TM) hemostatic powder sold in the market (70 times), after water absorption, the composite hemostatic powder is gelatinized, and the in vitro degradation time is 4 days.
Examples 8,
Weighing 200mg of four-arm polymerAn oxyethylene polyoxypropylene aldehyde group (as shown in formula I, wherein m is 25, n is 75, p is 30, x is 4, R is 1 Aldehyde group) with a particle size of 0.2 μm, and 200mg of a two-arm polyethylene glycol amino group (shown in formula VI, wherein m is 88, x is 2, R is weighed 2 Amino group) with the grain diameter of 0.5 mu m, and uniformly mixing the two synthetic powders with 200mg of chitosan water absorption powder to obtain the composite hemostatic powder.
The water absorption capacity of the composite hemostatic powder prepared in the example is 200 times of that of the chitosan water absorption powder, after water absorption, the composite hemostatic powder is gelatinized, and the in vitro degradation time is 3 days.
And (3) carrying out a porcine femoral artery cut-off hemostasis test: the left and right femoral arteries of the pig are exposed, cut off by using surgical scissors (figure 1), then hemostatic powder is coated on the hemostatic powder, the bleeding condition is observed every 30 seconds, the time required for observing the blood non-flowing is the hemostatic time, and the hemostatic effect graph of each embodiment is shown in the table I.
Table one: comparison of hemostatic effects of the composite hemostatic powders prepared in examples
Claims (9)
1. The composite hemostatic powder is characterized by being prepared by mixing two molecules of polyoxyethylene polyoxypropylene block copolymer, polyacrylic acid or polyethylene glycol derivative, synthetic molecule 1 and synthetic molecule 2, wherein the synthetic molecule 1 is any one of formula I, formula II and formula III:
in the formula I, the formula II or the formula III, m, n and p are 28 to 123, x is 1 to 8;
wherein R is 1 Is amino, amberAny one of imide ester, aldehyde group, mercapto group, alkenyl group, alkynyl group, acrylate group and methacrylate group; the synthetic molecule 2 is any one of formula IV, formula V or formula VI:
in the formula IV, the formula V or the formula VI, m, n and p are 2 to 88, x is 1 to 8 2 Is any one of amino, carboxyl, succinimide ester, aldehyde group, sulfhydryl, alkenyl, alkynyl and acrylate group;
wherein the synthetic molecule 1 and the synthetic molecule 2 are not simultaneously selected from the formula III and the formula VI;
the synthetic molecule 1 and the synthetic molecule 2 can form a chemical bond connection through a chemical reaction in blood to form a gel.
2. The composite hemostatic powder according to claim 1, wherein R is 1 Or R 2 Is amino, succinimidyl ester, mercapto, alkynyl or azide group.
3. The composite hemostatic powder according to claim 1, wherein the synthetic molecule 1 is any one of the following formulas 1) to 3):
1) As shown in formula I, wherein m is 10 to 35, n is 28 to 123, p is 10 to 50, x is 4, R is 1 Is amino, aldehyde or succinimide ester;
2) As shown in a formula II, wherein m is 38 to 112, x is 2 to 4, R 1 Is amino, mercapto or aldehyde group;
3) As shown in formula III, wherein m is 36, x is 2 1 Is an amino group.
4. The composite hemostatic powder according to claim 1, wherein the synthetic molecule 2 is any one of the following 1) to 3):
1) As shown in formula IV, wherein m is 10 to 52, n is 12 to 20, p is 30 to 98, x is 4, R is 2 Being succinimidyl esters, amino or mercapto groups
2) Shown as a formula V, wherein m is 28 to 88, x is 4 2 Is amino, alkenyl or succinimide ester
3) As shown in formula VI, wherein m is 28 to 88, x is 1 2 Is amino, succinimidyl ester or aldehyde group.
5. The composite hemostatic powder according to claim 3 or 4, wherein the composite hemostatic powder is composed of a compound represented by formula III, wherein m is 36, x is 4, R, and a compound represented by formula V, wherein m is 36, x is 4, R 1 Is amino or alkynyl; in the compound shown in the formula V, m is 28 to 46, x is 4 2 Is amino, alkenyl or succinimidyl ester.
6. The compound hemostatic powder according to claim 3 or 4, wherein the compound hemostatic powder is composed of a compound represented by formula II, wherein m is 70 to 112, x is 2 to 4, R is a compound represented by formula VI or a compound represented by formula IV 1 Is amino, mercapto or aldehyde group; in the compound shown in the formula VI, m is 56, x is 4, and R2 is alkenyl; in the compound shown in the formula IV, m is 52, n is 12, p is 98 and x is 2.
7. The composite hemostatic powder according to claim 1, wherein the average particle size of the synthetic molecules 1 and 2 is 0.01 to 10 μm.
8. The composite hemostatic powder according to claim 1, wherein the composite hemostatic powder further comprises a water absorbent powder, wherein the mass ratio of the synthetic molecule 1 to the synthetic molecule 2 to the water absorbent powder is 0.01 to 10.
9. The composite hemostatic powder according to claim 8, wherein the water-absorbing powder is regenerated cellulose hemostatic powder, chitosan hemostatic powder, starch hemostatic powder, collagen hemostatic powder, or zeolite hemostatic powder, and specifically comprises: fuhe and Tai degradable hemostatic powder, meisiter quick-acting hemostatic powder, languan hemostatic powder, alista hemostatic powder, aiwei Ding microfiber hemostatic collagen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110531300.2A CN113209357B (en) | 2021-05-14 | 2021-05-14 | Composite styptic powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110531300.2A CN113209357B (en) | 2021-05-14 | 2021-05-14 | Composite styptic powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113209357A CN113209357A (en) | 2021-08-06 |
| CN113209357B true CN113209357B (en) | 2023-02-17 |
Family
ID=77092095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110531300.2A Active CN113209357B (en) | 2021-05-14 | 2021-05-14 | Composite styptic powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113209357B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284146A (en) * | 2001-07-17 | 2008-10-15 | 巴克斯特国际有限公司 | Dry hemostatic compositions and methods for their preparation |
| WO2011124640A1 (en) * | 2010-04-07 | 2011-10-13 | Baxter International Inc. | Hemostatic sponge |
| CN103957949A (en) * | 2011-10-11 | 2014-07-30 | 巴克斯特国际公司 | Hemostatic compositions |
| CN105169469A (en) * | 2015-08-29 | 2015-12-23 | 北京诺康达医药科技有限公司 | Tissue sealant and preparation method and application thereof |
| CN108014365A (en) * | 2017-12-14 | 2018-05-11 | 沈伟 | A kind of sealer hydrogel and its kit and preparation method |
| CN108525016A (en) * | 2017-03-01 | 2018-09-14 | 中国科学院化学研究所 | PEG hydrogel and the preparation method and application thereof based on chemical bond capable of being fast degraded |
| CN109646709A (en) * | 2019-01-29 | 2019-04-19 | 青岛中腾生物技术有限公司 | A kind of medical hemostatic closed material of degradable absorption |
| CN110025821A (en) * | 2018-01-12 | 2019-07-19 | 北京环球利康科技有限公司 | Use the method for biocompatible hemostatic agent and the compositions-treated active hemorrhage of tissue sealant |
| CN111440310A (en) * | 2020-05-26 | 2020-07-24 | 中国科学院长春应用化学研究所 | Polyethylene glycol derivative, preparation method thereof and polyethylene glycol hydrogel capable of rapidly generating crosslinking reaction |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101338036B (en) * | 2007-07-06 | 2010-11-03 | 常州百瑞吉生物医药有限公司 | Biocompatible quick-gelatinizing hydrogels and method for preparing spray thereof |
| US8852558B2 (en) * | 2008-03-11 | 2014-10-07 | Materials Modification, Inc. | In situ formation of an artificial blockage to control bleeding by polymer expansion with hydrogen peroxide and platinum catalyst |
| US9149511B2 (en) * | 2011-06-30 | 2015-10-06 | Ethicon, Inc. | Procoagulant peptides and their derivatives and uses therefor |
| IN2014DN11041A (en) * | 2012-06-22 | 2015-09-25 | Z Medica Llc | |
| CN102911493A (en) * | 2012-09-28 | 2013-02-06 | 山东赛克赛斯药业科技有限公司 | Biodegradable medical hydrogel and preparation method and application thereof |
| CN104399109B (en) * | 2014-11-26 | 2018-02-02 | 沈伟 | A kind of gel hemostatic material composition and preparation method thereof |
| KR20190054476A (en) * | 2017-11-13 | 2019-05-22 | 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 | Medical Absorbent Structure for Hemostatis and Wound Healing Comprising Adhesive Hydrogel Layer |
| CN110240712B (en) * | 2019-05-09 | 2021-04-23 | 大连理工大学 | High-tensile, high-viscosity and self-healing double-network hydrogel for tissue adhesion and preparation method and application thereof |
| CN110522948B (en) * | 2019-08-29 | 2021-08-06 | 南京工业大学 | Injectable hydrogel and preparation method and application thereof |
| CN111265711B (en) * | 2020-03-09 | 2021-06-15 | 北京爱特康医疗科技有限公司 | Tissue sealant powder, preparation process thereof and tissue sealant |
| CN111909401B (en) * | 2020-08-14 | 2021-11-16 | 杭州仪文生物医药有限公司 | Bi-component cross-linked medical composite material, preparation method and application thereof |
-
2021
- 2021-05-14 CN CN202110531300.2A patent/CN113209357B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284146A (en) * | 2001-07-17 | 2008-10-15 | 巴克斯特国际有限公司 | Dry hemostatic compositions and methods for their preparation |
| WO2011124640A1 (en) * | 2010-04-07 | 2011-10-13 | Baxter International Inc. | Hemostatic sponge |
| CN103957949A (en) * | 2011-10-11 | 2014-07-30 | 巴克斯特国际公司 | Hemostatic compositions |
| CN105169469A (en) * | 2015-08-29 | 2015-12-23 | 北京诺康达医药科技有限公司 | Tissue sealant and preparation method and application thereof |
| CN108525016A (en) * | 2017-03-01 | 2018-09-14 | 中国科学院化学研究所 | PEG hydrogel and the preparation method and application thereof based on chemical bond capable of being fast degraded |
| CN108014365A (en) * | 2017-12-14 | 2018-05-11 | 沈伟 | A kind of sealer hydrogel and its kit and preparation method |
| CN110025821A (en) * | 2018-01-12 | 2019-07-19 | 北京环球利康科技有限公司 | Use the method for biocompatible hemostatic agent and the compositions-treated active hemorrhage of tissue sealant |
| CN109646709A (en) * | 2019-01-29 | 2019-04-19 | 青岛中腾生物技术有限公司 | A kind of medical hemostatic closed material of degradable absorption |
| CN111440310A (en) * | 2020-05-26 | 2020-07-24 | 中国科学院长春应用化学研究所 | Polyethylene glycol derivative, preparation method thereof and polyethylene glycol hydrogel capable of rapidly generating crosslinking reaction |
Non-Patent Citations (1)
| Title |
|---|
| Synthesis and properties of hemostatic and bacteria-responsive in situ hydrogels for emergency treatment in critical situations;Yazhong Bu et al;《ACS Applied Materials & Interfaces》;20160509;第12674-12683页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113209357A (en) | 2021-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10195312B2 (en) | Modified starch material of biocompatible hemostasis | |
| US20180022833A1 (en) | Microspheres of Hydrolysed Starch with Endogenous, Charged Ligands | |
| RU2759898C2 (en) | Superabsorbent polymer hydrogel xerogel sponge, method for production and application thereof | |
| CN110025821A (en) | Use the method for biocompatible hemostatic agent and the compositions-treated active hemorrhage of tissue sealant | |
| EP2203053B1 (en) | Modified starch material of biocompatible hemostasis | |
| ES2711416T3 (en) | Fast-acting dry sealant material and methods for its use and manufacture | |
| WO2018197946A1 (en) | Hydrogel compositions including fibers and methods of use thereof | |
| WO2009076873A1 (en) | A biocompatible denatured starch sponge material | |
| CN103957948A (en) | Hemostatic compositions | |
| US4530974A (en) | Nonthrombogenic articles having enhanced albumin affinity | |
| JP2002541923A (en) | Rapidly gelling biocompatible polymer composition | |
| CN113289052B (en) | Controllable cross-linking and degradation material and application thereof | |
| CN112898598A (en) | Tissue adhesion hydrogel and preparation method and application thereof | |
| CN113372585A (en) | Preparation method and application of hydrogel with high-adhesion composite function | |
| CN112999412B (en) | Hydrogel dressing for wound healing and preparation method thereof | |
| RU2739771C1 (en) | Tranexamic acid spray for knee joint arthroplasty | |
| CN109498833B (en) | Medical absorbable polysaccharide composite material and application thereof | |
| WO2009043839A1 (en) | Coalescing carboxymethylchitosan-based materials | |
| CN113209357B (en) | Composite styptic powder | |
| CN112023109B (en) | Self-repairing hemostatic film capable of being adhered and preparation method thereof | |
| CN113289051B (en) | PEG powder capable of being rapidly crosslinked and degraded and application thereof | |
| CN114848668A (en) | Composition with wound healing promoting and quick hemostasis functions | |
| CN113599568A (en) | Synthetic material powder and application thereof in hemostasis system | |
| CN112007202A (en) | Adhesive healing-promoting hemostatic sponge and preparation method thereof | |
| CN113350565B (en) | Medical adhesive material for vessel closure and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |